AKT1 and metabolic dysfunction-associated steatotic liver disease: Supporting these hypotheses, recently it has been shown that the suppression of IRS2/AKT signalling prevents hepatic steatosis, non-alcoholic fatty liver disease (NAFLD) and liver cancer57 indicating the importance of balance in the anabolic and catabolic response.